查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612664

乳癌診斷市場：按技術、按癌症類型、按組成部分、按診斷類型、按最終用戶分類 - 全球預測 2025-2030

Breast Cancer Diagnostics Market by Technique (Imaging, Molecular Testing, Tissue Biopsy Tests), Cancer Type (BRCA Breast Cancer, EGFR Mutation Test Breast Cancer, ER & PR Breast Cancer), Component, Diagnostic Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年乳癌診斷市值為65.4億美元，預計到2024年將達到70.4億美元，複合年成長率為7.79%，到2030年將達到110.6億美元。

乳癌診斷市場是腫瘤學的重要組成部分，其特點是用於乳癌檢測和診斷的技術和產品。這包括乳房X光攝影、超音波、MRI、切片檢查、先進的分子診斷等等。這些診斷對於早期發現疾病並顯著改善患者的治療效果至關重要。應用範圍涵蓋醫院、診斷中心和研究機構，滿足篩檢和診斷需求。透過早期準確的診斷，這些工具在治療計劃和患者管理中發揮著至關重要的作用，極大地影響了醫療保健。

主要市場統計
基準年[2023] 65.4億美元
預計年份 [2024] 70.4億美元
預測年份 [2030] 110.6億美元
複合年成長率（%） 7.79%

市場成長受到多種因素的推動，包括全球乳癌發生率上升、診斷技術的進步以及早期檢測意識的提高。此外，支持醫療保健政策和改善新興市場的醫療保健基礎設施將推動成長。診斷成像、液態切片和基因檢測領域的人工智慧和機器學習等技術創新正在創造新的機會。對個人化醫療的投資和不斷成長的數位醫療採用將進一步擴大市場格局。然而，市場限制包括先進診斷設備的高成本、監管障礙以及影響診斷可靠性和患者信任的誤報和漏報風險。

挑戰包括獲得醫療保健的地區差異，這影響了診斷工具的可用性和實施，以及公共衛生系統的預算限制，阻礙了新技術的引入。需要創新和研究的領域包括開發具有成本效益的非侵入性診斷測試以及增強具有更高靈敏度和特異性的診斷影像技術。遺傳和生物標記研究的進一步進展也可以帶來顯著的好處。為了抓住新的商機，相關人員應專注於夥伴關係策略，加強研發能力，並利用巨量資料分析來提高診斷的準確性和效率。市場正在動態發展，隨著技術創新的不斷變革，存在著巨大的成長空間。

市場動態：揭示快速發展的乳癌診斷市場的關鍵市場洞察

供需的動態交互作用正在改變乳癌診斷市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球乳癌發生率不斷上升
    • 乳癌診斷的有利報銷框架
    • 全球乳癌篩檢計畫的增加
  • 市場限制因素
    • 與乳癌診斷測試相關的高成本
  • 市場機會
    • 將人工智慧 (AI) 和機器學習 (ML) 整合到乳癌診斷中
    • 癌症診斷技術的持續研發活動
  • 市場挑戰
    • 缺乏熟練且訓練有素的專業人員

波特五力：開拓乳癌診斷市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對乳癌診斷市場的影響

外部宏觀環境因素在塑造乳癌診斷市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解乳癌診斷藥物市場的競爭狀況

乳癌診斷市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

乳癌診斷市場中的 FPNV 定位矩陣供應商績效評估

FPNV定位矩陣是評估乳癌診斷市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪乳癌診斷市場的成功之路

乳癌診斷市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球乳癌發生率上升
      • 乳癌診斷的有利報銷框架
      • 世界各地乳癌篩檢計畫不斷增加
    • 抑制因素
      • 乳癌診斷測試的高成本
    • 機會
      • 將人工智慧 (AI) 和機器學習 (ML) 整合到乳癌診斷中
      • 癌症診斷技術的持續研發活動
    • 任務
      • 缺乏熟練且訓練有素的專業人員
  • 市場區隔分析
    • 技術：分子生物學和基因組生物學的進步將提高分子檢測的普及率
    • 癌症類型：BRCA乳癌是一種遺傳性乳癌
    • 診斷類型：非電離成像技術在乳癌診斷的應用進展
    • 最終使用者：乳癌診斷藥物在診斷實驗室的採用率很高
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章乳癌診斷市場：依技術分類

  • 影像
    • 模擬乳房X光攝影
    • 乳房超音波系統
    • 數位乳房攝影
    • 乳房X光檢查
    • 核磁共振掃描
    • PET/ 電腦斷層掃描
  • 分子檢測
  • 組織切片檢查測試

第7章按癌症類型分類的乳癌診斷藥物市場

  • BRCA 乳癌
  • EGFR突變檢測乳癌
  • ER & PR 乳癌
  • HER2乳癌

第8章乳癌診斷市場：依組成部分

  • 消耗品
    • 抗體
    • 試劑套件和試劑
    • 探測
  • 裝置
    • 切片檢查儀器
    • 影像設備
    • 病理學設備

第9章按診斷類型分類的乳癌診斷藥物市場

  • 電離乳房攝影技術
  • 非電離成像技術

第 10 章乳癌診斷市場：依最終用戶分類

  • 診斷實驗室
  • 醫院及門診手術中心
  • 研究/學術機構

第11章 北美和南美乳癌診斷藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區乳癌診斷藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲乳癌診斷藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Solis Mammography 宣布收購 Carolina Breast Imaging
    • 強生 Impact Ventures 投資 Mamotest，以改善拉丁美洲乳癌患者獲得治療的機會
    • Sysmex Europe 將透過與 Cerca Biotech 簽訂的歐洲分銷協議銷售先進的乳癌診斷測試 MammaTyper。
  • 戰略分析和建議

公司名單

  • 4D Path Inc.
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • AstraZeneca PLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biocept, Inc.
  • Biodesix
  • Cardinal Health
  • Danaher Corporation
  • Epigenomics AG
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fluxion Biosciences Inc. by Cell Microsystems
  • FUJIFILM Holdings Corporation
  • General Electric Company
  • Hologic, Inc.
  • Illumina, Inc.
  • Koninklijke Philips NV
  • NanoString Technologies, Inc.
  • NeoGenomics Laboratories
  • Olea Medical
  • OncoGenomX
  • Paragon Biosciences LLC by Catalent, Inc.
  • Provista Diagnostics, Inc. by Todos Medical
  • Quest Diagnostics Incorporated
  • Siemens Healthcare Private Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-A26E0E57405A

The Breast Cancer Diagnostics Market was valued at USD 6.54 billion in 2023, expected to reach USD 7.04 billion in 2024, and is projected to grow at a CAGR of 7.79%, to USD 11.06 billion by 2030.

The Breast Cancer Diagnostics market is a critical component of oncology, characterized by techniques and products used for the detection and diagnosis of breast cancer. This includes mammography, ultrasound, MRI, biopsy, and advanced molecular diagnostics. These diagnostics are essential for early disease detection, improving patient outcomes significantly. The application spans hospitals, diagnostic centers, and research institutes, addressing both screening and diagnostic needs. Through early and accurate diagnosis, these tools play a pivotal role in treatment planning and patient management, thereby carrying significant healthcare implications.

KEY MARKET STATISTICS
Base Year [2023] USD 6.54 billion
Estimated Year [2024] USD 7.04 billion
Forecast Year [2030] USD 11.06 billion
CAGR (%) 7.79%

Market growth is driven by several factors, including the rising prevalence of breast cancer globally, advancements in diagnostic technology, and increased awareness about early detection. Additionally, supportive healthcare policies and improving healthcare infrastructure across emerging markets foster growth. Technological innovations such as AI and machine learning in imaging, liquid biopsies, and genetic testing are presenting new opportunities. Investments in personalized medicine and growing adoption of digital health further expand market prospects. However, market limitations include high costs of advanced diagnostic devices, regulatory hurdles, and the risk of false positives and negatives, which can affect diagnostic credibility and patient trust.

Challenging factors include the variability in healthcare access across regions, influencing the availability and adoption of diagnostic tools, and potential resistance to adopting new technologies due to budget constraints in public healthcare systems. Areas ripe for innovation and research include the development of cost-effective, non-invasive diagnostic tests, and enhanced imaging techniques with higher sensitivity and specificity. Further exploration into genetic and biomarker research could also yield substantial benefits. To capitalize on emerging opportunities, stakeholders should focus on partnership strategies, enhancing R&D capabilities, and leveraging big data analytics to improve diagnostic accuracy and efficiency. The market is dynamic and evolving, with substantial room for growth as innovations continue to transform breast cancer diagnostics.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Breast Cancer Diagnostics Market

The Breast Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidence of breast cancer globally
    • Favorable reimbursement framework for breast cancer diagnosis
    • Growing number of breast cancer screening programs worldwide
  • Market Restraints
    • High cost associated with breast cancer diagnostic tests
  • Market Opportunities
    • Integration of artificial intelligence (AI) and machine learning (ML) in breast cancer diagnostic
    • Ongoing research and development activities in cancer diagnostic techniques
  • Market Challenges
    • Dearth of the skilled and trained professionals

Porter's Five Forces: A Strategic Tool for Navigating the Breast Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Breast Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Breast Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Breast Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Breast Cancer Diagnostics Market

A detailed market share analysis in the Breast Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Breast Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Breast Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Breast Cancer Diagnostics Market

A strategic analysis of the Breast Cancer Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Breast Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include 4D Path Inc., Abbott Laboratories, Agilent Technologies, Inc., AstraZeneca PLC, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocept, Inc., Biodesix, Cardinal Health, Danaher Corporation, Epigenomics AG, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fluxion Biosciences Inc. by Cell Microsystems, FUJIFILM Holdings Corporation, General Electric Company, Hologic, Inc., Illumina, Inc., Koninklijke Philips N.V., NanoString Technologies, Inc., NeoGenomics Laboratories, Olea Medical, OncoGenomX, Paragon Biosciences LLC by Catalent, Inc., Provista Diagnostics, Inc. by Todos Medical, Quest Diagnostics Incorporated, Siemens Healthcare Private Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Breast Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technique, market is studied across Imaging, Molecular Testing, and Tissue Biopsy Tests. The Imaging is further studied across Analog Mammography, Breast Ultrasound System, Digital Mammography, Mammography, MRI Scan, and PET/CT Scan.
  • Based on Cancer Type, market is studied across BRCA Breast Cancer, EGFR Mutation Test Breast Cancer, ER & PR Breast Cancer, and HER 2 Breast Cancer.
  • Based on Component, market is studied across Consumables and Instruments. The Consumables is further studied across Antibodies, Kits & Reagents, and Probes. The Instruments is further studied across Biopsy Instruments, Imaging Instruments, and Pathology-Based Instruments.
  • Based on Diagnostic Type, market is studied across Ionizing Breast Imaging Technologies and Non-Ionizing Imaging Technologies.
  • Based on End-User, market is studied across Diagnostic Laboratories, Hospitals & Ambulatory Surgery Center, and Research & Academic Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of breast cancer globally
      • 5.1.1.2. Favorable reimbursement framework for breast cancer diagnosis
      • 5.1.1.3. Growing number of breast cancer screening programs worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with breast cancer diagnostic tests
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of artificial intelligence (AI) and machine learning (ML) in breast cancer diagnostic
      • 5.1.3.2. Ongoing research and development activities in cancer diagnostic techniques
    • 5.1.4. Challenges
      • 5.1.4.1. Dearth of the skilled and trained professionals
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technique: Advancements in molecular and genomic biology advancing the penetration of molecular testing
    • 5.2.2. Cancer Type: BRCA breast cancer is highly implicated as a hereditary breast cancer
    • 5.2.3. Diagnostic Type: Advancing applications of non-ionizing imaging technologies for breast cancer diagnostics
    • 5.2.4. End-User: High adoption of breast cancer diagnostics in the diagnostic laboratories
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Breast Cancer Diagnostics Market, by Technique

  • 6.1. Introduction
  • 6.2. Imaging
    • 6.2.1. Analog Mammography
    • 6.2.2. Breast Ultrasound System
    • 6.2.3. Digital Mammography
    • 6.2.4. Mammography
    • 6.2.5. MRI Scan
    • 6.2.6. PET/CT Scan
  • 6.3. Molecular Testing
  • 6.4. Tissue Biopsy Tests

7. Breast Cancer Diagnostics Market, by Cancer Type

  • 7.1. Introduction
  • 7.2. BRCA Breast Cancer
  • 7.3. EGFR Mutation Test Breast Cancer
  • 7.4. ER & PR Breast Cancer
  • 7.5. HER 2 Breast Cancer

8. Breast Cancer Diagnostics Market, by Component

  • 8.1. Introduction
  • 8.2. Consumables
    • 8.2.1. Antibodies
    • 8.2.2. Kits & Reagents
    • 8.2.3. Probes
  • 8.3. Instruments
    • 8.3.1. Biopsy Instruments
    • 8.3.2. Imaging Instruments
    • 8.3.3. Pathology-Based Instruments

9. Breast Cancer Diagnostics Market, by Diagnostic Type

  • 9.1. Introduction
  • 9.2. Ionizing Breast Imaging Technologies
  • 9.3. Non-Ionizing Imaging Technologies

10. Breast Cancer Diagnostics Market, by End-User

  • 10.1. Introduction
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals & Ambulatory Surgery Center
  • 10.4. Research & Academic Institutes

11. Americas Breast Cancer Diagnostics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Breast Cancer Diagnostics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Breast Cancer Diagnostics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Solis Mammography Announces Acquisition of Carolina Breast Imaging
    • 14.3.2. Johnson & Johnson Impact Ventures Invests in Mamotest to Improve Access to Care for Breast Cancer Patients in Latin America
    • 14.3.3. Sysmex Europe Distributes MammaTyper, an Advanced Breast Cancer Diagnostic Assay, Through The European Distribution Agreement With Cerca Biotech
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 4D Path Inc.
  • 2. Abbott Laboratories
  • 3. Agilent Technologies, Inc.
  • 4. AstraZeneca PLC
  • 5. Becton, Dickinson and Company
  • 6. Bio-Rad Laboratories, Inc.
  • 7. Biocept, Inc.
  • 8. Biodesix
  • 9. Cardinal Health
  • 10. Danaher Corporation
  • 11. Epigenomics AG
  • 12. Exact Sciences Corporation
  • 13. F. Hoffmann-La Roche Ltd.
  • 14. Fluxion Biosciences Inc. by Cell Microsystems
  • 15. FUJIFILM Holdings Corporation
  • 16. General Electric Company
  • 17. Hologic, Inc.
  • 18. Illumina, Inc.
  • 19. Koninklijke Philips N.V.
  • 20. NanoString Technologies, Inc.
  • 21. NeoGenomics Laboratories
  • 22. Olea Medical
  • 23. OncoGenomX
  • 24. Paragon Biosciences LLC by Catalent, Inc.
  • 25. Provista Diagnostics, Inc. by Todos Medical
  • 26. Quest Diagnostics Incorporated
  • 27. Siemens Healthcare Private Limited
  • 28. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. BREAST CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. BREAST CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. BREAST CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. BREAST CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BREAST CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BREAST CANCER DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ANALOG MAMMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BREAST ULTRASOUND SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL MAMMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PET/CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE BIOPSY TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY EGFR MUTATION TEST BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER & PR BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER 2 BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PROBES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY-BASED INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NON-IONIZING IMAGING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & AMBULATORY SURGERY CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. JAPAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. MALAYSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SINGAPORE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TAIWAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. THAILAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. VIETNAM BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. DENMARK BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. EGYPT BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. FINLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. FRANCE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. GERMANY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. ISRAEL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. ITALY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. NIGERIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. NORWAY BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. POLAND BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. QATAR BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. RUSSIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 316. SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 324. SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
  • TABLE 330. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 332. SPAI